FeesSafety
Pluang+

Northwest Biotherapeutics expands US team to boost cancer vaccine production and clinical trials.

Market News
26 Oct 2026, 18:16 WIB
PRNewsWire
View Source
Bullish
Northwest Biotherapeutics expands US team to boost cancer vaccine production and clinical trials.

Northwest Biotherapeutics has expanded its US technical team to enhance production capacity and prepare for clinical trials beyond brain cancer. The company hired key roles in Quality Assurance, IT, and Investor Relations while eliminating some non-essential positions to balance costs. This move supports scaling up manufacturing in the US as a backup to UK facilities and advancing personalized immune therapies for solid tumors. The company is also reviewing UK personnel to align with these priorities.

Northwest Biotherapeutics' expansion of its technical team provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 26, 2026 20:32 WIB: Among 150 priced US health-sector stocks, 89 rose and 50 fell today. Notable movers include NUWE at USD 0.31 with a 7.45% decline and a typical hold time of 29 days, WGS rising 5.79% to USD 59.40 with a 20-day hold, and NVAX down 4.12% at USD 9.30 with a 59-day hold time.

More News

Smithfield Foods launches $250K scholarship for business students at Christopher Newport University

Smithfield Foods launches $250K scholarship for business students at Christopher Newport University

Smithfield Foods has created a $250,000 Future Leaders Scholarship program at Christopher Newport University to support eight incoming business students with $7,500 annual scholarships renewable for up to four years. The program aims to help local st...

Others
Bullish
40 minutes ago
E-Power's Guizhou JV secures RMB 110M of RMB 200M capital raise, valuing it at RMB 2B post-money.

E-Power's Guizhou JV secures RMB 110M of RMB 200M capital raise, valuing it at RMB 2B post-money.

E-Power Inc.'s joint venture, Sunrise Guizhou, received RMB 110 million of a planned RMB 200 million capital increase, raising its registered capital and valuing the company at RMB 2 billion post-money. The funds will support business expansion, R&D,...

Company Fundamentals
Bullish
40 minutes ago
Tallinna Sadam secures €50M loan to refinance bonds maturing in 2026, extending debt to 2031.

Tallinna Sadam secures €50M loan to refinance bonds maturing in 2026, extending debt to 2031.

AS Tallinna Sadam has signed a €50 million unsecured loan agreement with Swedbank, with a 5-year term and interest based on 3-month Euribor plus a margin. The loan will be fully drawn on October 26, 2026, and matures on October 26, 2031. This financi...

Company Fundamentals
Neutral
1 hour ago
AS Tallinna Sadam secures €50M loan to redeem bonds, supporting port operations and growth.

AS Tallinna Sadam secures €50M loan to redeem bonds, supporting port operations and growth.

AS Tallinna Sadam signed a €50 million unsecured loan agreement with AS Swedbank, maturing in five years with an interest rate based on 3-month Euribor plus margin. The loan, drawn on October 26, 2026, will be used to redeem bonds worth €50.4 million...

Company Fundamentals
Neutral
1 hour ago
Vita Coco and Homesick launch limited-edition candles inspired by Vita Coco Treats flavors

Vita Coco and Homesick launch limited-edition candles inspired by Vita Coco Treats flavors

Vita Coco, a leading coconut water brand, has partnered with Homesick to create a limited-edition candle collection inspired by Vita Coco Treats flavors: Strawberries & Creme and Frosted Lemonade. The candles capture the essence of these flavors thro...

Others
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App